Bailard Inc. Has $90.10 Million Stock Position in Gilead Sciences, Inc. $GILD

Bailard Inc. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 734,057 shares of the biopharmaceutical company’s stock after acquiring an additional 65,056 shares during the quarter. Gilead Sciences comprises about 2.0% of Bailard Inc.’s investment portfolio, making the stock its 9th biggest holding. Bailard Inc.’s holdings in Gilead Sciences were worth $90,098,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Alpha Cubed Investments LLC grew its position in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Personal CFO Solutions LLC grew its position in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Moss Adams Wealth Advisors LLC grew its position in Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the last quarter. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 12.5% during the 4th quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 79 shares during the last quarter. Finally, SOA Wealth Advisors LLC. grew its position in Gilead Sciences by 8.7% during the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $133.52 on Tuesday. The firm’s 50-day moving average price is $139.07 and its 200-day moving average price is $132.99. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market cap of $165.77 billion, a PE ratio of 18.19 and a beta of 0.31. Gilead Sciences, Inc. has a 52-week low of $96.18 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.85 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GILD. Leerink Partners cut their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday. Morgan Stanley cut their price objective on shares of Gilead Sciences from $175.00 to $168.00 in a research report on Friday. Truist Financial reissued a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Finally, UBS Group increased their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $157.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead delivered Q1 revenue of $6.96 billion, up 4.4% year over year and ahead of expectations, while adjusted EPS of $2.03 also beat consensus. Management said full-year revenue should come in around $30.2 billion, roughly in line with Wall Street estimates, which supports the view that core operations remain stable. Article: GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
• Positive Sentiment: Analysts continue to see upside from Gilead’s HIV business and oncology pipeline, and Truist recently reiterated a Buy rating, which can help reinforce investor confidence in the stock. Article: Gilead Sciences Earns Buy Rating from Truist Financial
• Neutral Sentiment: Several firms have updated valuation models after the earnings release, including Rothschild & Co Redburn trimming its price target to $167 and RBC lowering its target to $122, reflecting a mixed analyst reaction rather than a clear shift in the long-term thesis. Article: Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 from $170
• Negative Sentiment: The biggest concern is Gilead’s sharply reduced fiscal 2026 EPS outlook, which now calls for a loss of $1.05 to $0.65 per share after accounting for about $11.5 billion in IPR&D and financing costs. That guidance cut is likely the main reason shares are facing pressure despite the earnings beat. Article: Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. The trade was a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock valued at $9,238,250 in the last 90 days. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.